Relay Therapeutics (RLAY) Interest Expenses (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Interest Expenses of $365000.0 for Q1 2026, down 59.93% year-over-year from $911000.0 in Q1 2025, and up 5983.33% quarter-over-quarter from $6000.0 in Q4 2025.
Relay Therapeutics (RLAY) Interest Expenses (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Interest Expenses for 8 consecutive years, with $365000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 59.93% year-over-year to $365000.0; the TTM figure through Mar 2026 stood at $365000.0 (down 59.93% YoY), while the FY2025 annual figure was $480.5 million, up 11.25% from the prior year.
- Interest Expenses rose to $365000.0 in Q1 2026 per RLAY's latest filing, from $6000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $431.9 million in Q4 2024 and bottomed at $6000.0 in Q4 2025.
- Historically, Interest Expenses has averaged $29.7 million across 5 years, with a median of $3.4 million in 2023.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 22945.0% — and 2025, when it tumbled 100.0%.
- Relay Therapeutics' Interest Expenses stood at $7.6 million in 2022, then surged by 149.47% to $18.9 million in 2023, then surged by 2184.49% to $431.9 million in 2024, then sank by 100.0% to $6000.0 in 2025, then surged by 5983.33% to $365000.0 in 2026.
- Business Quant data shows RLAY's Interest Expenses at $365000.0 in Q1 2026, $6000.0 in Q4 2025, and $239000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | 1.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.61 Mn |
| Jun 30, 2026 | 1.61 Mn |
| Mar 31, 2026 | 365,000.00 |
| Mar 31, 2026 | 365,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 239,000.00 |
| Sep 30, 2025 | 239,000.00 |
| Jun 30, 2025 | 4.24 Mn |
| Jun 30, 2025 | 4.24 Mn |
| Mar 31, 2025 | 911,000.00 |
| Mar 31, 2025 | 911,000.00 |
| Dec 31, 2024 | 431.93 Mn |
| Dec 31, 2024 | 431.93 Mn |
| Sep 30, 2024 | 298,000.00 |
| Sep 30, 2024 | 298,000.00 |
| Jun 30, 2024 | 1.35 Mn |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.30 Mn |